-
Mashup Score: 28AACR Annual Meeting 2024 - 1 month(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28AACR Annual Meeting 2024 - 1 month(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: General Medicine News, Hem/OncsTweet-
It's a great honour🙏 to chair the Tumor Evolution & Heterogeneity Section of #AACR24 in San Diego https://t.co/IINrk0duna Submit your 🔥🔥 #CancerEvo abstract to help make this meeting a success and maybe get the opportunity to present on the big stage! Deadline: Nov 16th‼️
-
-
Mashup Score: 28AACR Annual Meeting 2024 - 2 month(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: General Medicine News, Hem/OncsTweet-
It's a great honour🙏 to chair the Tumor Evolution & Heterogeneity Section of #AACR24 in San Diego https://t.co/IINrk0duna Submit your 🔥🔥 #CancerEvo abstract to help make this meeting a success and maybe get the opportunity to present on the big stage! Deadline: Nov 16th‼️
-
-
Mashup Score: 25
Mismatch repair-deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens, which make these tumours immunogenic and many respond to immune checkpoint inhibitors. The MMRd hypermutator phe…
Categories: General Medicine News, Hem/OncsTweet-
-Parallel evolution which surpasses even that in RCC! -Big headache for biomarker development! Our study on ITH in dMMR CRCs is out: https://t.co/TMl731SW7f High mutation supply and strong immune selection pressures make this a great model tumor for #CancerEvo studies
-
-
Mashup Score: 4AACR Annual Meeting 2024 - 7 month(s) ago
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Source: www.aacr.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
It's a great honour🙏 to chair the Tumor Evolution & Heterogeneity Section of #AACR24 in San Diego https://t.co/IINrk0duna Submit your 🔥🔥 #CancerEvo abstract to help make this meeting a success and maybe get the opportunity to present on the big stage! Deadline: Nov 16th‼️
-
-
Mashup Score: 3items - Jobs - 1 year(s) ago
Department: Barts Cancer InstituteSalary: £36,348 – £42,592 per annum (Grade 4)Reference: QMUL31987Location: Charterhouse SquareDate posted: 14 February 2023Closing date: 27 March 2023Further details and applyOverviewAbout the Role Applications are sought for an experienced Post Doc who will lead a new gastro-oesophageal cancer research study. The project aims to develop more effective…
Source: www.qmul.ac.ukCategories: Hem/Oncs, Latest HeadlinesTweet-
🔥🔥🔥We have two exciting post-doc positions in cancer immunotherapy!! Unravelling T cell antigens using PDOs, immuno-peptidomics and functional T cell assays. Focus on gastro-oesophageal cancer https://t.co/sW7EeOkMGH and colorectal cancer https://t.co/mZsOqV1rcP
-
-
Mashup Score: 0γδ T cells are effectors of immunotherapy in cancers with HLA class I defects - Nature - 1 year(s) ago
γδ T cells contribute to the response to immune checkpoint blockade treatment in patients with HLA-class-I-negative DNA mismatch repair-deficient colon cancers. .
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
γδ T-cells are effectors in MMRd cancers with B2M loss from Voest lab in Nature https://t.co/TyWhS7oGix A hell of a paper - maybe THE paper of 2023, although I am conscious I am sticking my head out saying this in February. Reasons are.... 1/2
-
-
Mashup Score: 3Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer - 1 year(s) ago
Woolston et al. show that in metastatic colorectal cancer cetuximab resistance can be conferred by genetic mechanisms, such as NF1 loss or RAS/RAF alterations, or by transcriptomic changes that induce a stroma-rich phenotype. They also provide a rationale for combining cetuximab with immunotherapy.
Source: Cancer CellCategories: Hem/Oncs, Latest HeadlinesTweet-
Fantastic to see our previous findings on EGFR antibody resistance-evolution in CRC (https://t.co/YdTa2yOSsk, https://t.co/KUVLGdBVyw) validated in this large ctDNA study https://t.co/LyM2g3qBa8 1. There is an unexplained resistance gap: no known genetic resistance drivers... 1/6
-
-
Mashup Score: 0@marcogerlinger's Profile / Post. - 1 year(s) ago
Marco Gerlinger@marcogerlingerOncologist and scientist1 Posts3 Following0 FollowersMedical Oncologist and Clinician Scientist at Barts Cancer Institute and St Bartholomew’s Hospital. Cancer therapeutics, immunotherapy and biomarkers – all in the context of Darwinian Evolution. Director of GI Cancer Research at St Barts Hospital
Source: post.newsCategories: Hem/Oncs, Latest HeadlinesTweet-
As scientists (and many others of course) know - always good to have a plan B: https://t.co/HWx79GdhNj
-
-
Mashup Score: 1ESMO Immuno-Oncology Congress 2022 - 1 year(s) ago
The ESMO Immuno-Oncology Congress will take place as an onsite event in Geneva, Switzerland, 7-9 December 2022, as well as online
Source: www.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @BartsGI_Cancer: End of year wrap up of immunotherapy progress in GI cancer at #ESMOImmuno22 congress today https://t.co/nwiEL2ZKte. Cha…
-
It's a great honour🙏 to chair the Tumor Evolution & Heterogeneity Section of #AACR24 in San Diego https://t.co/IINrk0duna Submit your 🔥🔥 #CancerEvo abstract to help make this meeting a success and maybe get the opportunity to present on the big stage! Deadline: Nov 16th‼️